nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—NPY1R—prostate gland—urinary bladder cancer	0.0199	0.113	CbGeAlD
Atomoxetine—CYP2C19—urine—urinary bladder cancer	0.0177	0.101	CbGeAlD
Atomoxetine—NPY1R—seminal vesicle—urinary bladder cancer	0.0168	0.0957	CbGeAlD
Atomoxetine—NPY1R—renal system—urinary bladder cancer	0.0136	0.0771	CbGeAlD
Atomoxetine—HTR2A—urine—urinary bladder cancer	0.0113	0.0643	CbGeAlD
Atomoxetine—NPY1R—female reproductive system—urinary bladder cancer	0.0109	0.0618	CbGeAlD
Atomoxetine—CYP3A4—urine—urinary bladder cancer	0.0105	0.0596	CbGeAlD
Atomoxetine—CYP2D6—urine—urinary bladder cancer	0.0103	0.0586	CbGeAlD
Atomoxetine—NPY1R—vagina—urinary bladder cancer	0.00982	0.0559	CbGeAlD
Atomoxetine—Pseudoephedrine—IL2—urinary bladder cancer	0.00638	0.331	CrCbGaD
Atomoxetine—NPY1R—lymph node—urinary bladder cancer	0.00635	0.0361	CbGeAlD
Atomoxetine—Benzphetamine—POR—urinary bladder cancer	0.00568	0.294	CrCbGaD
Atomoxetine—HTR1B—female reproductive system—urinary bladder cancer	0.00461	0.0262	CbGeAlD
Atomoxetine—HTR1D—female reproductive system—urinary bladder cancer	0.00446	0.0254	CbGeAlD
Atomoxetine—HTR2C—female reproductive system—urinary bladder cancer	0.00442	0.0251	CbGeAlD
Atomoxetine—SLC6A4—female reproductive system—urinary bladder cancer	0.00419	0.0238	CbGeAlD
Atomoxetine—SLC6A2—female reproductive system—urinary bladder cancer	0.00369	0.021	CbGeAlD
Atomoxetine—CYP2C19—vagina—urinary bladder cancer	0.00314	0.0179	CbGeAlD
Atomoxetine—HTR2A—epithelium—urinary bladder cancer	0.00298	0.017	CbGeAlD
Atomoxetine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00287	0.0164	CbGeAlD
Atomoxetine—Ketoprofen—CXCL8—urinary bladder cancer	0.00284	0.147	CrCbGaD
Atomoxetine—HTR2A—renal system—urinary bladder cancer	0.00277	0.0157	CbGeAlD
Atomoxetine—CYP3A4—renal system—urinary bladder cancer	0.00256	0.0146	CbGeAlD
Atomoxetine—CYP2D6—renal system—urinary bladder cancer	0.00252	0.0143	CbGeAlD
Atomoxetine—HTR2A—female reproductive system—urinary bladder cancer	0.00222	0.0126	CbGeAlD
Atomoxetine—SLC6A2—lymph node—urinary bladder cancer	0.00216	0.0123	CbGeAlD
Atomoxetine—Pseudoephedrine—TNF—urinary bladder cancer	0.00215	0.112	CrCbGaD
Atomoxetine—CYP3A4—female reproductive system—urinary bladder cancer	0.00205	0.0117	CbGeAlD
Atomoxetine—CYP2D6—female reproductive system—urinary bladder cancer	0.00202	0.0115	CbGeAlD
Atomoxetine—HTR2A—vagina—urinary bladder cancer	0.002	0.0114	CbGeAlD
Atomoxetine—Fenoprofen—PTGS2—urinary bladder cancer	0.0014	0.0728	CrCbGaD
Atomoxetine—Anorexia—Etoposide—urinary bladder cancer	0.000971	0.00141	CcSEcCtD
Atomoxetine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00097	0.00141	CcSEcCtD
Atomoxetine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000966	0.00141	CcSEcCtD
Atomoxetine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000966	0.00141	CcSEcCtD
Atomoxetine—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000961	0.0014	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00096	0.0014	CcSEcCtD
Atomoxetine—Infestation NOS—Methotrexate—urinary bladder cancer	0.000957	0.00139	CcSEcCtD
Atomoxetine—Infestation—Methotrexate—urinary bladder cancer	0.000957	0.00139	CcSEcCtD
Atomoxetine—Depression—Methotrexate—urinary bladder cancer	0.000954	0.00139	CcSEcCtD
Atomoxetine—Pain—Cisplatin—urinary bladder cancer	0.000951	0.00138	CcSEcCtD
Atomoxetine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000943	0.00137	CcSEcCtD
Atomoxetine—Dysuria—Epirubicin—urinary bladder cancer	0.000939	0.00137	CcSEcCtD
Atomoxetine—Dizziness—Thiotepa—urinary bladder cancer	0.000938	0.00136	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000933	0.00136	CcSEcCtD
Atomoxetine—Urticaria—Fluorouracil—urinary bladder cancer	0.000932	0.00136	CcSEcCtD
Atomoxetine—Conjunctivitis—Methotrexate—urinary bladder cancer	0.00093	0.00135	CcSEcCtD
Atomoxetine—Influenza—Doxorubicin—urinary bladder cancer	0.000929	0.00135	CcSEcCtD
Atomoxetine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000927	0.00135	CcSEcCtD
Atomoxetine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000927	0.00135	CcSEcCtD
Atomoxetine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000916	0.00133	CcSEcCtD
Atomoxetine—Paraesthesia—Etoposide—urinary bladder cancer	0.000915	0.00133	CcSEcCtD
Atomoxetine—Weight decreased—Epirubicin—urinary bladder cancer	0.000908	0.00132	CcSEcCtD
Atomoxetine—Somnolence—Etoposide—urinary bladder cancer	0.000905	0.00132	CcSEcCtD
Atomoxetine—Vomiting—Thiotepa—urinary bladder cancer	0.000902	0.00131	CcSEcCtD
Atomoxetine—Infestation NOS—Epirubicin—urinary bladder cancer	0.000895	0.0013	CcSEcCtD
Atomoxetine—Infestation—Epirubicin—urinary bladder cancer	0.000895	0.0013	CcSEcCtD
Atomoxetine—Rash—Thiotepa—urinary bladder cancer	0.000894	0.0013	CcSEcCtD
Atomoxetine—Dermatitis—Thiotepa—urinary bladder cancer	0.000893	0.0013	CcSEcCtD
Atomoxetine—Headache—Thiotepa—urinary bladder cancer	0.000888	0.00129	CcSEcCtD
Atomoxetine—Decreased appetite—Etoposide—urinary bladder cancer	0.000885	0.00129	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000879	0.00128	CcSEcCtD
Atomoxetine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000879	0.00128	CcSEcCtD
Atomoxetine—Fatigue—Etoposide—urinary bladder cancer	0.000878	0.00128	CcSEcCtD
Atomoxetine—Pain—Etoposide—urinary bladder cancer	0.000871	0.00127	CcSEcCtD
Atomoxetine—Constipation—Etoposide—urinary bladder cancer	0.000871	0.00127	CcSEcCtD
Atomoxetine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.00087	0.00127	CcSEcCtD
Atomoxetine—Dysuria—Doxorubicin—urinary bladder cancer	0.000869	0.00126	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000863	0.00126	CcSEcCtD
Atomoxetine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000858	0.00125	CcSEcCtD
Atomoxetine—Asthenia—Gemcitabine—urinary bladder cancer	0.000856	0.00125	CcSEcCtD
Atomoxetine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000848	0.00123	CcSEcCtD
Atomoxetine—Pruritus—Gemcitabine—urinary bladder cancer	0.000844	0.00123	CcSEcCtD
Atomoxetine—Nausea—Thiotepa—urinary bladder cancer	0.000842	0.00123	CcSEcCtD
Atomoxetine—Urethral disorder—Methotrexate—urinary bladder cancer	0.000842	0.00123	CcSEcCtD
Atomoxetine—Weight decreased—Doxorubicin—urinary bladder cancer	0.00084	0.00122	CcSEcCtD
Atomoxetine—Sinusitis—Epirubicin—urinary bladder cancer	0.00084	0.00122	CcSEcCtD
Atomoxetine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000839	0.00122	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000833	0.00121	CcSEcCtD
Atomoxetine—Pruritus—Fluorouracil—urinary bladder cancer	0.00083	0.00121	CcSEcCtD
Atomoxetine—Ketoprofen—PTGS2—urinary bladder cancer	0.000829	0.043	CrCbGaD
Atomoxetine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000828	0.00121	CcSEcCtD
Atomoxetine—Infestation—Doxorubicin—urinary bladder cancer	0.000828	0.00121	CcSEcCtD
Atomoxetine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000816	0.00119	CcSEcCtD
Atomoxetine—Urticaria—Etoposide—urinary bladder cancer	0.000809	0.00118	CcSEcCtD
Atomoxetine—Abdominal pain—Etoposide—urinary bladder cancer	0.000805	0.00117	CcSEcCtD
Atomoxetine—Body temperature increased—Etoposide—urinary bladder cancer	0.000805	0.00117	CcSEcCtD
Atomoxetine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000805	0.00117	CcSEcCtD
Atomoxetine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000802	0.00117	CcSEcCtD
Atomoxetine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.0008	0.00116	CcSEcCtD
Atomoxetine—Asthenia—Cisplatin—urinary bladder cancer	0.000798	0.00116	CcSEcCtD
Atomoxetine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000797	0.00116	CcSEcCtD
Atomoxetine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000794	0.00116	CcSEcCtD
Atomoxetine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000788	0.00115	CcSEcCtD
Atomoxetine—Angiopathy—Methotrexate—urinary bladder cancer	0.000779	0.00113	CcSEcCtD
Atomoxetine—Sinusitis—Doxorubicin—urinary bladder cancer	0.000777	0.00113	CcSEcCtD
Atomoxetine—Dizziness—Fluorouracil—urinary bladder cancer	0.000776	0.00113	CcSEcCtD
Atomoxetine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000774	0.00113	CcSEcCtD
Atomoxetine—Chills—Methotrexate—urinary bladder cancer	0.00077	0.00112	CcSEcCtD
Atomoxetine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000761	0.00111	CcSEcCtD
Atomoxetine—Vomiting—Gemcitabine—urinary bladder cancer	0.000758	0.0011	CcSEcCtD
Atomoxetine—Mental disorder—Methotrexate—urinary bladder cancer	0.000752	0.00109	CcSEcCtD
Atomoxetine—Rash—Gemcitabine—urinary bladder cancer	0.000752	0.00109	CcSEcCtD
Atomoxetine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000751	0.00109	CcSEcCtD
Atomoxetine—Malnutrition—Methotrexate—urinary bladder cancer	0.000748	0.00109	CcSEcCtD
Atomoxetine—Headache—Gemcitabine—urinary bladder cancer	0.000747	0.00109	CcSEcCtD
Atomoxetine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000746	0.00109	CcSEcCtD
Atomoxetine—Flushing—Epirubicin—urinary bladder cancer	0.000746	0.00109	CcSEcCtD
Atomoxetine—Vomiting—Fluorouracil—urinary bladder cancer	0.000746	0.00109	CcSEcCtD
Atomoxetine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.00074	0.00108	CcSEcCtD
Atomoxetine—Rash—Fluorouracil—urinary bladder cancer	0.000739	0.00108	CcSEcCtD
Atomoxetine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000739	0.00108	CcSEcCtD
Atomoxetine—Headache—Fluorouracil—urinary bladder cancer	0.000735	0.00107	CcSEcCtD
Atomoxetine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000734	0.00107	CcSEcCtD
Atomoxetine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000732	0.00107	CcSEcCtD
Atomoxetine—Asthenia—Etoposide—urinary bladder cancer	0.000731	0.00106	CcSEcCtD
Atomoxetine—Angiopathy—Epirubicin—urinary bladder cancer	0.000729	0.00106	CcSEcCtD
Atomoxetine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000729	0.00106	CcSEcCtD
Atomoxetine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000724	0.00105	CcSEcCtD
Atomoxetine—Back pain—Methotrexate—urinary bladder cancer	0.000723	0.00105	CcSEcCtD
Atomoxetine—Chills—Epirubicin—urinary bladder cancer	0.000721	0.00105	CcSEcCtD
Atomoxetine—Pruritus—Etoposide—urinary bladder cancer	0.000721	0.00105	CcSEcCtD
Atomoxetine—Nausea—Gemcitabine—urinary bladder cancer	0.000708	0.00103	CcSEcCtD
Atomoxetine—Vomiting—Cisplatin—urinary bladder cancer	0.000707	0.00103	CcSEcCtD
Atomoxetine—Vision blurred—Methotrexate—urinary bladder cancer	0.000704	0.00103	CcSEcCtD
Atomoxetine—Mental disorder—Epirubicin—urinary bladder cancer	0.000704	0.00102	CcSEcCtD
Atomoxetine—Rash—Cisplatin—urinary bladder cancer	0.000701	0.00102	CcSEcCtD
Atomoxetine—Dermatitis—Cisplatin—urinary bladder cancer	0.0007	0.00102	CcSEcCtD
Atomoxetine—Malnutrition—Epirubicin—urinary bladder cancer	0.0007	0.00102	CcSEcCtD
Atomoxetine—Diarrhoea—Etoposide—urinary bladder cancer	0.000697	0.00101	CcSEcCtD
Atomoxetine—Nausea—Fluorouracil—urinary bladder cancer	0.000697	0.00101	CcSEcCtD
Atomoxetine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00069	0.001	CcSEcCtD
Atomoxetine—Flushing—Doxorubicin—urinary bladder cancer	0.00069	0.001	CcSEcCtD
Atomoxetine—Flatulence—Epirubicin—urinary bladder cancer	0.000689	0.001	CcSEcCtD
Atomoxetine—Tension—Epirubicin—urinary bladder cancer	0.000686	0.000999	CcSEcCtD
Atomoxetine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000685	0.000997	CcSEcCtD
Atomoxetine—Nervousness—Epirubicin—urinary bladder cancer	0.000679	0.000989	CcSEcCtD
Atomoxetine—Back pain—Epirubicin—urinary bladder cancer	0.000677	0.000985	CcSEcCtD
Atomoxetine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000675	0.000982	CcSEcCtD
Atomoxetine—Dizziness—Etoposide—urinary bladder cancer	0.000674	0.00098	CcSEcCtD
Atomoxetine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000673	0.000979	CcSEcCtD
Atomoxetine—Vertigo—Methotrexate—urinary bladder cancer	0.000672	0.000977	CcSEcCtD
Atomoxetine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00067	0.000975	CcSEcCtD
Atomoxetine—Chills—Doxorubicin—urinary bladder cancer	0.000667	0.000971	CcSEcCtD
Atomoxetine—Nausea—Cisplatin—urinary bladder cancer	0.00066	0.000961	CcSEcCtD
Atomoxetine—Vision blurred—Epirubicin—urinary bladder cancer	0.000659	0.00096	CcSEcCtD
Atomoxetine—Cough—Methotrexate—urinary bladder cancer	0.000652	0.000949	CcSEcCtD
Atomoxetine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000651	0.000948	CcSEcCtD
Atomoxetine—Convulsion—Methotrexate—urinary bladder cancer	0.000648	0.000943	CcSEcCtD
Atomoxetine—Vomiting—Etoposide—urinary bladder cancer	0.000648	0.000943	CcSEcCtD
Atomoxetine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000647	0.000942	CcSEcCtD
Atomoxetine—Agitation—Epirubicin—urinary bladder cancer	0.000643	0.000936	CcSEcCtD
Atomoxetine—Rash—Etoposide—urinary bladder cancer	0.000642	0.000935	CcSEcCtD
Atomoxetine—Dermatitis—Etoposide—urinary bladder cancer	0.000642	0.000934	CcSEcCtD
Atomoxetine—Headache—Etoposide—urinary bladder cancer	0.000638	0.000929	CcSEcCtD
Atomoxetine—Flatulence—Doxorubicin—urinary bladder cancer	0.000638	0.000928	CcSEcCtD
Atomoxetine—Myalgia—Methotrexate—urinary bladder cancer	0.000636	0.000926	CcSEcCtD
Atomoxetine—Arthralgia—Methotrexate—urinary bladder cancer	0.000636	0.000926	CcSEcCtD
Atomoxetine—Chest pain—Methotrexate—urinary bladder cancer	0.000636	0.000926	CcSEcCtD
Atomoxetine—Tension—Doxorubicin—urinary bladder cancer	0.000635	0.000924	CcSEcCtD
Atomoxetine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000634	0.000923	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000632	0.00092	CcSEcCtD
Atomoxetine—Nervousness—Doxorubicin—urinary bladder cancer	0.000629	0.000915	CcSEcCtD
Atomoxetine—Vertigo—Epirubicin—urinary bladder cancer	0.000628	0.000915	CcSEcCtD
Atomoxetine—Syncope—Epirubicin—urinary bladder cancer	0.000627	0.000913	CcSEcCtD
Atomoxetine—Back pain—Doxorubicin—urinary bladder cancer	0.000626	0.000911	CcSEcCtD
Atomoxetine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000622	0.000906	CcSEcCtD
Atomoxetine—Palpitations—Epirubicin—urinary bladder cancer	0.000618	0.0009	CcSEcCtD
Atomoxetine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000615	0.000895	CcSEcCtD
Atomoxetine—Cough—Epirubicin—urinary bladder cancer	0.00061	0.000888	CcSEcCtD
Atomoxetine—Vision blurred—Doxorubicin—urinary bladder cancer	0.00061	0.000888	CcSEcCtD
Atomoxetine—Convulsion—Epirubicin—urinary bladder cancer	0.000606	0.000882	CcSEcCtD
Atomoxetine—Infection—Methotrexate—urinary bladder cancer	0.000606	0.000882	CcSEcCtD
Atomoxetine—Nausea—Etoposide—urinary bladder cancer	0.000605	0.000881	CcSEcCtD
Atomoxetine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000598	0.000871	CcSEcCtD
Atomoxetine—Myalgia—Epirubicin—urinary bladder cancer	0.000596	0.000867	CcSEcCtD
Atomoxetine—Arthralgia—Epirubicin—urinary bladder cancer	0.000596	0.000867	CcSEcCtD
Atomoxetine—Chest pain—Epirubicin—urinary bladder cancer	0.000596	0.000867	CcSEcCtD
Atomoxetine—Agitation—Doxorubicin—urinary bladder cancer	0.000595	0.000866	CcSEcCtD
Atomoxetine—Anxiety—Epirubicin—urinary bladder cancer	0.000593	0.000864	CcSEcCtD
Atomoxetine—Skin disorder—Methotrexate—urinary bladder cancer	0.000593	0.000862	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000591	0.000861	CcSEcCtD
Atomoxetine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00059	0.000858	CcSEcCtD
Atomoxetine—Dry mouth—Epirubicin—urinary bladder cancer	0.000582	0.000848	CcSEcCtD
Atomoxetine—Vertigo—Doxorubicin—urinary bladder cancer	0.000582	0.000846	CcSEcCtD
Atomoxetine—Anorexia—Methotrexate—urinary bladder cancer	0.000582	0.000846	CcSEcCtD
Atomoxetine—Syncope—Doxorubicin—urinary bladder cancer	0.00058	0.000845	CcSEcCtD
Atomoxetine—Palpitations—Doxorubicin—urinary bladder cancer	0.000572	0.000833	CcSEcCtD
Atomoxetine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000569	0.000828	CcSEcCtD
Atomoxetine—Infection—Epirubicin—urinary bladder cancer	0.000567	0.000826	CcSEcCtD
Atomoxetine—Cough—Doxorubicin—urinary bladder cancer	0.000565	0.000822	CcSEcCtD
Atomoxetine—Shock—Epirubicin—urinary bladder cancer	0.000562	0.000818	CcSEcCtD
Atomoxetine—Convulsion—Doxorubicin—urinary bladder cancer	0.000561	0.000816	CcSEcCtD
Atomoxetine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00056	0.000815	CcSEcCtD
Atomoxetine—Tachycardia—Epirubicin—urinary bladder cancer	0.000557	0.000811	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000556	0.000809	CcSEcCtD
Atomoxetine—Skin disorder—Epirubicin—urinary bladder cancer	0.000555	0.000807	CcSEcCtD
Atomoxetine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000552	0.000803	CcSEcCtD
Atomoxetine—Insomnia—Methotrexate—urinary bladder cancer	0.000552	0.000803	CcSEcCtD
Atomoxetine—Chest pain—Doxorubicin—urinary bladder cancer	0.000551	0.000802	CcSEcCtD
Atomoxetine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000551	0.000802	CcSEcCtD
Atomoxetine—Myalgia—Doxorubicin—urinary bladder cancer	0.000551	0.000802	CcSEcCtD
Atomoxetine—Anxiety—Doxorubicin—urinary bladder cancer	0.000549	0.000799	CcSEcCtD
Atomoxetine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000548	0.000797	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000547	0.000797	CcSEcCtD
Atomoxetine—Anorexia—Epirubicin—urinary bladder cancer	0.000544	0.000792	CcSEcCtD
Atomoxetine—Somnolence—Methotrexate—urinary bladder cancer	0.000542	0.000789	CcSEcCtD
Atomoxetine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000539	0.000784	CcSEcCtD
Atomoxetine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000537	0.000782	CcSEcCtD
Atomoxetine—Decreased appetite—Methotrexate—urinary bladder cancer	0.00053	0.000772	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000527	0.000767	CcSEcCtD
Atomoxetine—Fatigue—Methotrexate—urinary bladder cancer	0.000526	0.000766	CcSEcCtD
Atomoxetine—Infection—Doxorubicin—urinary bladder cancer	0.000525	0.000764	CcSEcCtD
Atomoxetine—Pain—Methotrexate—urinary bladder cancer	0.000522	0.000759	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00052	0.000757	CcSEcCtD
Atomoxetine—Shock—Doxorubicin—urinary bladder cancer	0.00052	0.000756	CcSEcCtD
Atomoxetine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000518	0.000754	CcSEcCtD
Atomoxetine—Insomnia—Epirubicin—urinary bladder cancer	0.000516	0.000752	CcSEcCtD
Atomoxetine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000516	0.00075	CcSEcCtD
Atomoxetine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000513	0.000747	CcSEcCtD
Atomoxetine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000513	0.000746	CcSEcCtD
Atomoxetine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000511	0.000743	CcSEcCtD
Atomoxetine—Somnolence—Epirubicin—urinary bladder cancer	0.000508	0.000739	CcSEcCtD
Atomoxetine—Anorexia—Doxorubicin—urinary bladder cancer	0.000504	0.000733	CcSEcCtD
Atomoxetine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000503	0.000732	CcSEcCtD
Atomoxetine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000503	0.000731	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000499	0.000726	CcSEcCtD
Atomoxetine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000496	0.000722	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000493	0.000717	CcSEcCtD
Atomoxetine—Fatigue—Epirubicin—urinary bladder cancer	0.000492	0.000716	CcSEcCtD
Atomoxetine—Pain—Epirubicin—urinary bladder cancer	0.000488	0.000711	CcSEcCtD
Atomoxetine—Constipation—Epirubicin—urinary bladder cancer	0.000488	0.000711	CcSEcCtD
Atomoxetine—Urticaria—Methotrexate—urinary bladder cancer	0.000485	0.000705	CcSEcCtD
Atomoxetine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000482	0.000702	CcSEcCtD
Atomoxetine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000482	0.000702	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000481	0.0007	CcSEcCtD
Atomoxetine—Insomnia—Doxorubicin—urinary bladder cancer	0.000478	0.000695	CcSEcCtD
Atomoxetine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000474	0.00069	CcSEcCtD
Atomoxetine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00047	0.000685	CcSEcCtD
Atomoxetine—Somnolence—Doxorubicin—urinary bladder cancer	0.00047	0.000684	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000467	0.000679	CcSEcCtD
Atomoxetine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000465	0.000677	CcSEcCtD
Atomoxetine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000459	0.000668	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000456	0.000664	CcSEcCtD
Atomoxetine—Fatigue—Doxorubicin—urinary bladder cancer	0.000455	0.000663	CcSEcCtD
Atomoxetine—Urticaria—Epirubicin—urinary bladder cancer	0.000454	0.00066	CcSEcCtD
Atomoxetine—Pain—Doxorubicin—urinary bladder cancer	0.000452	0.000657	CcSEcCtD
Atomoxetine—Constipation—Doxorubicin—urinary bladder cancer	0.000452	0.000657	CcSEcCtD
Atomoxetine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000451	0.000657	CcSEcCtD
Atomoxetine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000451	0.000657	CcSEcCtD
Atomoxetine—Asthenia—Methotrexate—urinary bladder cancer	0.000438	0.000637	CcSEcCtD
Atomoxetine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000435	0.000634	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000432	0.000629	CcSEcCtD
Atomoxetine—Pruritus—Methotrexate—urinary bladder cancer	0.000432	0.000628	CcSEcCtD
Atomoxetine—Urticaria—Doxorubicin—urinary bladder cancer	0.00042	0.000611	CcSEcCtD
Atomoxetine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000418	0.000608	CcSEcCtD
Atomoxetine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000418	0.000608	CcSEcCtD
Atomoxetine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000417	0.000608	CcSEcCtD
Atomoxetine—Asthenia—Epirubicin—urinary bladder cancer	0.00041	0.000596	CcSEcCtD
Atomoxetine—Pruritus—Epirubicin—urinary bladder cancer	0.000404	0.000588	CcSEcCtD
Atomoxetine—Dizziness—Methotrexate—urinary bladder cancer	0.000403	0.000587	CcSEcCtD
Atomoxetine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000391	0.000569	CcSEcCtD
Atomoxetine—Vomiting—Methotrexate—urinary bladder cancer	0.000388	0.000565	CcSEcCtD
Atomoxetine—Rash—Methotrexate—urinary bladder cancer	0.000385	0.00056	CcSEcCtD
Atomoxetine—Dermatitis—Methotrexate—urinary bladder cancer	0.000384	0.000559	CcSEcCtD
Atomoxetine—Headache—Methotrexate—urinary bladder cancer	0.000382	0.000556	CcSEcCtD
Atomoxetine—Asthenia—Doxorubicin—urinary bladder cancer	0.000379	0.000552	CcSEcCtD
Atomoxetine—Dizziness—Epirubicin—urinary bladder cancer	0.000378	0.000549	CcSEcCtD
Atomoxetine—Pruritus—Doxorubicin—urinary bladder cancer	0.000374	0.000544	CcSEcCtD
Atomoxetine—Vomiting—Epirubicin—urinary bladder cancer	0.000363	0.000528	CcSEcCtD
Atomoxetine—Nausea—Methotrexate—urinary bladder cancer	0.000362	0.000527	CcSEcCtD
Atomoxetine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000361	0.000526	CcSEcCtD
Atomoxetine—Rash—Epirubicin—urinary bladder cancer	0.00036	0.000524	CcSEcCtD
Atomoxetine—Dermatitis—Epirubicin—urinary bladder cancer	0.00036	0.000523	CcSEcCtD
Atomoxetine—Headache—Epirubicin—urinary bladder cancer	0.000358	0.000521	CcSEcCtD
Atomoxetine—Dizziness—Doxorubicin—urinary bladder cancer	0.000349	0.000508	CcSEcCtD
Atomoxetine—Nausea—Epirubicin—urinary bladder cancer	0.000339	0.000494	CcSEcCtD
Atomoxetine—Vomiting—Doxorubicin—urinary bladder cancer	0.000336	0.000489	CcSEcCtD
Atomoxetine—Rash—Doxorubicin—urinary bladder cancer	0.000333	0.000485	CcSEcCtD
Atomoxetine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000333	0.000484	CcSEcCtD
Atomoxetine—Headache—Doxorubicin—urinary bladder cancer	0.000331	0.000482	CcSEcCtD
Atomoxetine—Nausea—Doxorubicin—urinary bladder cancer	0.000314	0.000457	CcSEcCtD
Atomoxetine—HTR1D—Signaling Pathways—JAG1—urinary bladder cancer	7.16e-05	0.000607	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MMP9—urinary bladder cancer	7.04e-05	0.000597	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CDKN1A—urinary bladder cancer	7.02e-05	0.000595	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—JAG1—urinary bladder cancer	7.01e-05	0.000595	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PTEN—urinary bladder cancer	7e-05	0.000594	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CXCL8—urinary bladder cancer	6.98e-05	0.000592	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	6.84e-05	0.000581	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EP300—urinary bladder cancer	6.68e-05	0.000566	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	6.67e-05	0.000566	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SRC—urinary bladder cancer	6.49e-05	0.000551	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—HRAS—urinary bladder cancer	6.48e-05	0.00055	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	6.31e-05	0.000535	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—RHOA—urinary bladder cancer	6.1e-05	0.000517	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	6.07e-05	0.000515	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CXCL8—urinary bladder cancer	6.06e-05	0.000514	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—RHOA—urinary bladder cancer	6.05e-05	0.000513	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RBX1—urinary bladder cancer	5.94e-05	0.000503	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—RHOA—urinary bladder cancer	5.93e-05	0.000503	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—S100B—urinary bladder cancer	5.84e-05	0.000496	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MYC—urinary bladder cancer	5.82e-05	0.000493	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.81e-05	0.000493	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—S100B—urinary bladder cancer	5.8e-05	0.000492	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TYMP—urinary bladder cancer	5.8e-05	0.000492	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	5.75e-05	0.000488	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	5.75e-05	0.000488	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EGFR—urinary bladder cancer	5.69e-05	0.000483	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—S100B—urinary bladder cancer	5.68e-05	0.000481	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TSC1—urinary bladder cancer	5.58e-05	0.000473	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.57e-05	0.000472	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—RHOA—urinary bladder cancer	5.54e-05	0.00047	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—RHOA—urinary bladder cancer	5.5e-05	0.000466	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—RHOA—urinary bladder cancer	5.38e-05	0.000456	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—KRAS—urinary bladder cancer	5.38e-05	0.000456	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.35e-05	0.000454	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	5.33e-05	0.000452	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.31e-05	0.000451	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—JAG1—urinary bladder cancer	5.31e-05	0.000451	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	5.26e-05	0.000446	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NCOR1—urinary bladder cancer	5.25e-05	0.000446	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NAT2—urinary bladder cancer	5.24e-05	0.000445	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NCOR1—urinary bladder cancer	5.21e-05	0.000442	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.2e-05	0.000441	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RBX1—urinary bladder cancer	5.15e-05	0.000437	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—IL2—urinary bladder cancer	5.12e-05	0.000434	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NCOR1—urinary bladder cancer	5.1e-05	0.000433	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—IL2—urinary bladder cancer	5.08e-05	0.000431	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—IL2—urinary bladder cancer	4.97e-05	0.000422	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CXCL8—urinary bladder cancer	4.86e-05	0.000412	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSC1—urinary bladder cancer	4.85e-05	0.000411	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CXCL8—urinary bladder cancer	4.82e-05	0.000409	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.82e-05	0.000409	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—urinary bladder cancer	4.78e-05	0.000405	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	4.74e-05	0.000402	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CXCL8—urinary bladder cancer	4.72e-05	0.000401	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL2—urinary bladder cancer	4.65e-05	0.000394	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TERT—urinary bladder cancer	4.63e-05	0.000393	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—JAG1—urinary bladder cancer	4.61e-05	0.000391	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL2—urinary bladder cancer	4.61e-05	0.000391	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TERT—urinary bladder cancer	4.59e-05	0.00039	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—HRAS—urinary bladder cancer	4.57e-05	0.000388	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—RRM2—urinary bladder cancer	4.53e-05	0.000384	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL2—urinary bladder cancer	4.51e-05	0.000383	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TERT—urinary bladder cancer	4.5e-05	0.000382	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—RHOA—urinary bladder cancer	4.49e-05	0.000381	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	4.47e-05	0.00038	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	4.36e-05	0.00037	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—S100B—urinary bladder cancer	4.3e-05	0.000365	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—FGFR3—urinary bladder cancer	4.25e-05	0.00036	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—FGFR3—urinary bladder cancer	4.22e-05	0.000358	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ENO2—urinary bladder cancer	4.19e-05	0.000356	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	4.19e-05	0.000356	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.17e-05	0.000353	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	4.16e-05	0.000353	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—FGFR3—urinary bladder cancer	4.13e-05	0.00035	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ESR1—urinary bladder cancer	4.13e-05	0.00035	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ESR1—urinary bladder cancer	4.09e-05	0.000347	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—RHOA—urinary bladder cancer	4.08e-05	0.000346	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	4.06e-05	0.000345	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ESR1—urinary bladder cancer	4.01e-05	0.00034	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4e-05	0.00034	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.94e-05	0.000334	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—RHOA—urinary bladder cancer	3.9e-05	0.000331	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NCOR1—urinary bladder cancer	3.87e-05	0.000328	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.85e-05	0.000327	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.85e-05	0.000327	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL2—urinary bladder cancer	3.77e-05	0.00032	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.74e-05	0.000317	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—S100B—urinary bladder cancer	3.74e-05	0.000317	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CREBBP—urinary bladder cancer	3.62e-05	0.000307	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CREBBP—urinary bladder cancer	3.59e-05	0.000304	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCL8—urinary bladder cancer	3.58e-05	0.000304	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF1—urinary bladder cancer	3.57e-05	0.000303	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EGFR—urinary bladder cancer	3.55e-05	0.000301	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF1—urinary bladder cancer	3.54e-05	0.000301	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—RHOA—urinary bladder cancer	3.54e-05	0.0003	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EGFR—urinary bladder cancer	3.53e-05	0.000299	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CREBBP—urinary bladder cancer	3.51e-05	0.000298	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.49e-05	0.000296	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF1—urinary bladder cancer	3.47e-05	0.000294	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EGFR—urinary bladder cancer	3.45e-05	0.000293	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.42e-05	0.00029	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL2—urinary bladder cancer	3.42e-05	0.00029	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TERT—urinary bladder cancer	3.41e-05	0.000289	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	3.38e-05	0.000287	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NCOR1—urinary bladder cancer	3.36e-05	0.000285	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—KRAS—urinary bladder cancer	3.36e-05	0.000285	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—KRAS—urinary bladder cancer	3.33e-05	0.000283	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.28e-05	0.000278	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL2—urinary bladder cancer	3.27e-05	0.000278	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RHOA—urinary bladder cancer	3.27e-05	0.000277	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—KRAS—urinary bladder cancer	3.26e-05	0.000277	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RHOA—urinary bladder cancer	3.25e-05	0.000275	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RHOA—urinary bladder cancer	3.18e-05	0.00027	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.15e-05	0.000267	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FGFR3—urinary bladder cancer	3.13e-05	0.000265	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCL8—urinary bladder cancer	3.11e-05	0.000264	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.11e-05	0.000264	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ESR1—urinary bladder cancer	3.04e-05	0.000258	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ERBB2—urinary bladder cancer	3.03e-05	0.000257	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ERBB2—urinary bladder cancer	3.01e-05	0.000255	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL2—urinary bladder cancer	2.97e-05	0.000252	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TERT—urinary bladder cancer	2.96e-05	0.000251	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ERBB2—urinary bladder cancer	2.94e-05	0.00025	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCL8—urinary bladder cancer	2.87e-05	0.000244	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.86e-05	0.000242	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HRAS—urinary bladder cancer	2.85e-05	0.000242	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCL8—urinary bladder cancer	2.85e-05	0.000242	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HRAS—urinary bladder cancer	2.83e-05	0.00024	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.82e-05	0.000239	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCL8—urinary bladder cancer	2.79e-05	0.000237	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HRAS—urinary bladder cancer	2.77e-05	0.000235	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—urinary bladder cancer	2.74e-05	0.000233	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.73e-05	0.000231	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—urinary bladder cancer	2.72e-05	0.000231	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.72e-05	0.000231	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FGFR3—urinary bladder cancer	2.72e-05	0.00023	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCND1—urinary bladder cancer	2.68e-05	0.000227	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—urinary bladder cancer	2.67e-05	0.000226	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CREBBP—urinary bladder cancer	2.66e-05	0.000226	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCND1—urinary bladder cancer	2.66e-05	0.000225	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ESR1—urinary bladder cancer	2.64e-05	0.000224	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1—urinary bladder cancer	2.63e-05	0.000223	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.62e-05	0.000222	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—urinary bladder cancer	2.62e-05	0.000222	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCND1—urinary bladder cancer	2.6e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—urinary bladder cancer	2.6e-05	0.00022	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.59e-05	0.00022	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.59e-05	0.00022	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.59e-05	0.00022	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDKN1A—urinary bladder cancer	2.59e-05	0.00022	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTEN—urinary bladder cancer	2.58e-05	0.000219	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—urinary bladder cancer	2.58e-05	0.000219	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDKN1A—urinary bladder cancer	2.57e-05	0.000218	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTEN—urinary bladder cancer	2.56e-05	0.000217	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—urinary bladder cancer	2.52e-05	0.000214	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.52e-05	0.000214	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.52e-05	0.000214	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDKN1A—urinary bladder cancer	2.52e-05	0.000213	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTEN—urinary bladder cancer	2.51e-05	0.000213	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.48e-05	0.00021	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	2.47e-05	0.00021	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EP300—urinary bladder cancer	2.46e-05	0.000209	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.44e-05	0.000207	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EP300—urinary bladder cancer	2.44e-05	0.000207	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.43e-05	0.000206	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.41e-05	0.000204	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	2.41e-05	0.000204	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SRC—urinary bladder cancer	2.39e-05	0.000203	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EP300—urinary bladder cancer	2.39e-05	0.000203	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.38e-05	0.000202	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.38e-05	0.000202	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SRC—urinary bladder cancer	2.38e-05	0.000202	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SRC—urinary bladder cancer	2.33e-05	0.000197	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	2.31e-05	0.000196	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.29e-05	0.000194	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	2.28e-05	0.000194	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.28e-05	0.000193	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	2.27e-05	0.000193	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.24e-05	0.00019	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	2.23e-05	0.000189	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	2.15e-05	0.000182	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—urinary bladder cancer	2.15e-05	0.000182	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	2.13e-05	0.000181	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	2.11e-05	0.000179	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.1e-05	0.000179	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	2.1e-05	0.000178	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—urinary bladder cancer	2.1e-05	0.000178	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	2.09e-05	0.000177	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	2.09e-05	0.000177	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	2.08e-05	0.000177	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	2.04e-05	0.000173	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.03e-05	0.000172	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	2.02e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KRAS—urinary bladder cancer	1.98e-05	0.000168	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.97e-05	0.000167	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	1.97e-05	0.000167	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.94e-05	0.000164	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	1.93e-05	0.000163	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.91e-05	0.000162	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.91e-05	0.000162	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.9e-05	0.000161	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.86e-05	0.000157	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.84e-05	0.000156	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.82e-05	0.000155	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	1.81e-05	0.000154	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.78e-05	0.000151	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	1.76e-05	0.00015	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—urinary bladder cancer	1.76e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	1.76e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	1.75e-05	0.000148	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	1.71e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	1.71e-05	0.000145	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.71e-05	0.000145	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.69e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	1.69e-05	0.000143	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	1.67e-05	0.000142	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	1.66e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.66e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	1.65e-05	0.00014	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.64e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	1.64e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	1.58e-05	0.000134	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.58e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	1.57e-05	0.000134	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.56e-05	0.000132	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.56e-05	0.000132	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	1.55e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	1.53e-05	0.00013	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.49e-05	0.000126	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.46e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	1.46e-05	0.000124	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.46e-05	0.000124	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.38e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	1.37e-05	0.000116	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.34e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	1.34e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	1.3e-05	0.00011	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.27e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	1.27e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	1.24e-05	0.000105	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.21e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.17e-05	9.93e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	1.13e-05	9.56e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.12e-05	9.47e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.12e-05	9.46e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	1.08e-05	9.14e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.07e-05	9.09e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	8.78e-06	7.45e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	7.66e-06	6.49e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—EP300—urinary bladder cancer	7.3e-06	6.19e-05	CbGpPWpGaD
